Skip to main content

Kevin Kim, MD, MHS

Academic Title:


Primary Appointment:

Diagnostic Radiology and Nuclear Medicine

Administrative Title:

Chief, Division of Vascular and Interventional Radiology



Phone (Primary):

(410) 328-3478

Education and Training

1988 - 1991     B.A., Molecular & Cell Biology, University of California at Berkeley                   

1991 - 1993     Harvard University School of Dental Medicine        

1993 - 1995     M.D., Medical College of Virginia, School of Medicine

2017                  M.A. (privatim), Yale University

2018 - 2020     M.H.S., Yale University School of Medicine, Translational and Clinical Science  


Dr. Kim is a board certified interventional radiologist whose clinical and research interests are interventional radiology and interventional oncology, including image-guided therapies for oncological diseases. Dr. Kim has devloped clinical programs in neuroendocrine and hepatocellular oncology and oligometastasis.

Research/Clinical Keywords

interventional radiology, interventional oncology, image-guided therapies

Awards and Affiliations

2019    Top Doctor by Castle Connolly Medical, awarded for distinguished performance in teaching

2020    Top Doctor by Castle Connolly Medical, awarded for distinguished performance in teaching

2020    Yale Cancer Center Award for Clinical Excellence, Yale School of Medicine, awarded for distinguished performance in cancer medicine

2020    Fellow of the American College of Radiology (FACR), awarded for distinguished performance in teaching

Grants and Contracts

Active Grants

03/01/20 – 02/28/26       (Co-Inv 10%) PI: P. LoRusso

                                                VICKtOrY Early Clinical Trials Consortium”       

                                                NIH NCI UM1 CA186689

Total Direct Costs:      $6,292,877

Co-Investigator – coordinating multi-sites, evaluating quality and performing tissue sampling

The major goals of this project are to 1) leverage novel scientific discoveries for translation into early phase trials, using the CTEP pharmacopeia, in rare cancers, common cancers, and uncommon variants of common cancers; 2) incorporate serum, tissue and imaging biomarkers to better understand the effects of novel agents either alone or in combination; 3) train early career investigators to be knowledgeable and proficient in conducting early phase clinical trials by providing clinical research leadership opportunities and mentoring; and 4) include as a component of our early phase clinical trial recruitment, no less than 10% underserved/special populations.